Evidence map›Paper›PMID 40349901›Full record

SynthesisActa biomaterialia2025

Dissolving microneedles for nucleic acid delivery: A systematic search, review, and data synthesis.

Carmen I Tobos, Kim A Woodrow

Abstract readSystematic Review
In one paragraph

Synthesis in Acta biomaterialia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Carmen I TobosDepartment of Bioengineering, University of Washington, 3720 15th Ave NE, Seattle, WA 98195, USA.
Kim A WoodrowDepartment of Bioengineering, University of Washington, 3720 15th Ave NE, Seattle, WA 98195, USA. Electronic address: woodrow@uw.edu.

Funding

Drug-eluting fibers for on-demand and extended protection against HIVR01AI145483 · NIAID · UNIVERSITY OF WASHINGTON · PI WOODROW, KIM A. · 2019 to 2023
$4.0M
A low-profile copper intrauterine device that delivers long-acting contraception anR01AI150325 · NIAID · UNIVERSITY OF WASHINGTON · PI JENSEN, JEFFREY T., WOODROW, KIM A. · 2020 to 2024
$3.7M
An integrated fiber-microneedle device to study and optimize immune responsesR56DE028539 · NIDCR · UNIVERSITY OF WASHINGTON · PI FULLER, DEBORAH H., WOODROW, KIM A. · 2020 to 2020
$745k
NIAID NIH HHS R01 AI145483NIAID NIH HHS R01 AI150325NIDCR NIH HHS R56 DE028539
6 · The paper itself

Abstract

Dissolving microneedles deliver many classes of nucleic acids, overcoming susceptibility to enzymatic cleavage and poor intracellular delivery. Understanding the impact of microneedle formulation on nucleic acid therapeutic efficacy is critical for clinical translation. Here, we performed a systematic search to identify preclinical dissolving microneedle studies that deliver nucleic acid therapeutics including aptamers, DNA enzymes, mRNA, miRNA, plasmid DNA, recombinant viral vectors, and siRNA. This review quantitatively synthesizes preclinical data to identify correlations between microneedle form and function. Factors such as polymer molecular weight and incorporation of a nucleic acid carrier strongly influence mechanical and biological properties, while other design parameters allow for more flexibility. Altogether, 83 % of studies show equivalent or superior efficacy to existing nucleic acid administration routes including topical, subcutaneous, and intramuscular administration. Data especially supports the use of dissolving microneedles for viral and cancer vaccine applications, with a growing body of work exploring their utility for gene silencing. Nonetheless, several knowledge gaps remain. Emerging nucleic acid carrier chemistries that retain efficacy with improved toxicity profiles will define the next generation of formulations. Plasmid DNA and viral vectors show excellent long-term stability in dissolving microneedles, but further characterization is needed for long RNA transcripts. Finally, future work could explore the potential for non-dermal administration routes, as well as co-delivery of nucleic acids with small molecules to leverage synergistic effects. STATEMENT OF SIGNIFICANCE: This review comprehensively, critically, and quantitatively synthesizes preclinical dissolving microneedles for nucleic acid delivery. This approach identifies empirically supported correlations between microneedle form and function, highlighting evidence-based best practices and remaining challenges. The form-function relationships identified in this review will be valuable to those within the immediate microneedle field, as well as more broadly to audiences interested in nucleic acid therapeutics, drug delivery systems, microfabrication, and delivery strategies for low resource settings.

Indexed as

Drug Delivery SystemsGene Transfer TechniquesNeedlesNucleic AcidsAnimalsHumansNucleic AcidsDissolving microneedleDNAGene deliveryNucleic acidRNA

Identifiers

PMID40349901
PMCPMC12226010

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.